CCAP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Crescent Capital BDC Inc (CCAP) is not a strong buy for a long-term beginner investor at this time. The stock's recent financial performance, negative industry sentiment, and lack of significant positive catalysts suggest limited upside potential. Holding the stock may be a better option until clearer growth signals emerge.
The MACD histogram is positive and expanding, indicating a bullish trend. However, the RSI is in the neutral zone, and moving averages are converging, showing no clear momentum. The stock is trading near its resistance level of 13.296, which may limit immediate upside potential.
The amendment to the Investment Company Act has eased leverage limits, offering more funding flexibility. Gross margin increased by 1.10% YoY in the latest quarter.
Economic uncertainty, high inflation, and declining interest rates are raising concerns about asset quality and profitability. The SBIC & Commercial Finance industry ranks low, indicating poor earnings prospects. Recent financial performance shows declining revenue (-8.66% YoY), net income (-15.02% YoY), and EPS (-14.81% YoY).
In 2025/Q4, Crescent Capital BDC's revenue dropped to $32.82M (-8.66% YoY), net income dropped to $8.49M (-15.02% YoY), and EPS dropped to $0.23 (-14.81% YoY). However, gross margin increased to 87.37% (+1.10% YoY).
Analysts are mixed on CCAP. Keefe Bruyette maintains an Outperform rating with a price target of $15, while B. Riley initiated coverage with a Neutral rating and a $13.50 price target. Wells Fargo has an Equal Weight rating with a lowered price target of $13, reflecting cautious optimism about fee and dividend adjustments.
